{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T10:10:20Z","timestamp":1681899020986},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1003","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Abnormalities in the serum concentrations of calcium, phosphate, parathyroid hormone and vitamin D develop with declining renal function, leading in turn to renal osteodystrophy. Observational data now suggest that these disturbances in bone and mineral metabolism play an important role in the development of vascular calcification and subsequent cardiovascular disease, contributing to the high burden of cardiovascular disease within this population. A new nomenclature\u2014\u201cchronic kidney disease mineral and bone disorder\u201d\u2014has been introduced to describe this broader clinical syndrome and reflect the new emphasis that has been placed upon its management. This article describes the current therapeutic options for this condition, focusing particularly on the novel medications and strategies that have recently been introduced, and highlighting promising therapeutic possibilities for the future.<\/jats:p>","DOI":"10.1136\/pgmj.2008.075515","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T17:43:37Z","timestamp":1244742217000},"page":"274-279","source":"Crossref","is-referenced-by-count":2,"title":["Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder"],"prefix":"10.1093","volume":"85","author":[{"given":"A","family":"Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,6,11]]},"reference":[{"key":"2023041909290525800_b1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00005792-194305000-00002","article-title":"Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (AT 10) and iron","volume":"22","author":"Liu","year":"1943","journal-title":"Medicine"},{"key":"2023041909290525800_b2","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2023041909290525800_b3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041909290525800_b4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"2023041909290525800_b5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2023041909290525800_b6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"(Suppl 3)","key":"2023041909290525800_b7","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2023041909290525800_b8","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2023041909290525800_b9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/14728214.12.3.355","article-title":"Emerging drugs for hyperphosphatemia","volume":"12","author":"Bellinghieri","year":"2007","journal-title":"Expert Opin Emerg Drugs"},{"key":"2023041909290525800_b10","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1046\/j.1523-1755.2001.59780190.x","article-title":"Phosphate removal and hemodialysis conditions","volume":"78","author":"Pohlmeier","year":"2001","journal-title":"Kidney Int"},{"key":"2023041909290525800_b11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1525-139X.2007.00368.x","article-title":"Calcium balance during hemodialysis","volume":"21","author":"McIntyre","year":"2008","journal-title":"Semin Dial"},{"key":"2023041909290525800_b12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ncpneph0189","article-title":"Reappraisal of 2003 NKF-K\/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients","volume":"2","author":"Monge","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"issue":"(Suppl 5)","key":"2023041909290525800_b13","doi-asserted-by":"crossref","first-page":"V59","DOI":"10.1093\/ndt\/gfh1058","article-title":"Vascular calcification in patients with end-stage renal disease","volume":"19","author":"Floege","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2023041909290525800_b14","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1681\/ASN.2007050622","article-title":"Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD","volume":"19","author":"London","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2023041909290525800_b15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","article-title":"Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification","volume":"62","author":"Braun","year":"2004","journal-title":"Clin Nephrol"},{"key":"2023041909290525800_b16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"2023041909290525800_b17","first-page":"755A","article-title":"Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis. A randomized, open label, dose-titration study of PB-94 versus Caltan [abstract]","volume":"12","author":"Kinugasa","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2023041909290525800_b18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"2023041909290525800_b19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1081\/JDI-65259","article-title":"Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients","volume":"27","author":"Yamada","year":"2005","journal-title":"Ren Fail"},{"key":"2023041909290525800_b20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"2023041909290525800_b21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000096410","article-title":"Practical approaches to management of hyperphosphataemia: can we improve the current situation?","volume":"25","author":"Kuhlmann","year":"2007","journal-title":"Blood Purif"},{"key":"2023041909290525800_b22","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/ndt\/gfh282","article-title":"Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open label study with lanthanum carbonate","volume":"19","author":"Hutchinson","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2023041909290525800_b23","doi-asserted-by":"crossref","first-page":"c61","DOI":"10.1159\/000088932","article-title":"Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study","volume":"102","author":"Hutchinson","year":"2006","journal-title":"Nephrol Clin Pract"},{"key":"2023041909290525800_b24","first-page":"270A","article-title":"No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years","volume":"15","author":"Malluche","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2023041909290525800_b25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ndt\/14.4.863","article-title":"Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients","volume":"14","author":"Hergesell","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2023041909290525800_b26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","article-title":"Nicotinamide suppresses hyperphosphatemia in hemodialysis patients","volume":"65","author":"Takahashi","year":"2004","journal-title":"Kidney Int"},{"key":"2023041909290525800_b27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11255-006-0001-x","article-title":"Extended release nicotinic acid \u2013 a novel oral agent for phosphate control","volume":"38","author":"Sampathkumar","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"2023041909290525800_b28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023041909290525800_b29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","article-title":"The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure","volume":"29","author":"Martinez","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"2023041909290525800_b30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000183383","article-title":"Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24, 25-dihydroxyvitamin D","volume":"39","author":"Rickers","year":"1985","journal-title":"Nephron"},{"key":"2023041909290525800_b31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2023041909290525800_b32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2023041909290525800_b33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfm177","article-title":"Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies","volume":"22","author":"Drueke","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2023041909290525800_b34","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1046\/j.1523-1755.1998.00951.x","article-title":"Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats","volume":"53","author":"Schwarz","year":"1998","journal-title":"Kidney Int"},{"key":"2023041909290525800_b35","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0002-9440(10)64129-6","article-title":"A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis","volume":"158","author":"Makibayashi","year":"2001","journal-title":"Am J Pathol"},{"issue":"(Suppl 10)","key":"2023041909290525800_b36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/17.suppl_10.10","article-title":"Vitamin D analogues for secondary hyperparathyroidism","volume":"11","author":"Brown","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2023041909290525800_b37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2023041909290525800_b38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041909290525800_b39","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"20","author":"Moe","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2023041909290525800_b40","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041909290525800_b41","first-page":"CD006254","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients [Review]","volume":"(4)","author":"Strippoli","year":"2006","journal-title":"Cochrane Database Systematic Rev"},{"key":"2023041909290525800_b42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"2023041909290525800_b43","first-page":"892A","article-title":"Evaluation of cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial [Abstract PUB359]","volume":"17","author":"Chertow","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2023041909290525800_b44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1523-1755.2000.00837.x","article-title":"Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism","volume":"57","author":"Wada","year":"2000","journal-title":"Kidney Int"},{"key":"2023041909290525800_b45","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1003\/274\/50020317\/postgradmedj-85-274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1003\/274\/50020317\/postgradmedj-85-274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:39:31Z","timestamp":1681897171000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/85\/1003\/274\/7007441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":45,"journal-issue":{"issue":"1003","published-online":{"date-parts":[[2009,6,11]]},"published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2008.075515","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,5]]},"published":{"date-parts":[[2009,5,1]]}}}